Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Commentary|Podcasts|October 2, 2026
FDA Approval Insights: Ropeginterferon Alfa-2b Ushers in Long-Awaited New Treatment Option for Essential Thrombocythemia
Author(s)Ruben A. Mesa, MD, FACP
Fact checked by: Chris Ryan, Ashling Wahner
Ruben Mesa, MD, FACP, details the significance of the FDA approval of ropeginterferon alfa-2b for essential thrombocythemia.
Advertisement
Welcome to OncLive On Air®! I’m your host today, Chris Ryan.
OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive On Air covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.
In today’s episode, we welcomed Ruben Mesa, MD, FACP, who outlined the significance of
In the exclusive interview, Dr Mesa discussed what the FDA approval of ropeginterferon alfa-2b means for the essential thrombocythemia treatment paradigm, detailed the key efficacy and safety findings from the phase 3 SURPASS-ET trial (NCT04285086) that supported the approval, and looked ahead to other research that could continue to affect this space.
_____
That’s all we have for today! Thank you for listening to this episode of OncLive On Air. Check back throughout the week for exclusive interviews with leading experts in the oncology field.
For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.
OncLive is also on social media. On X and BlueSky, follow us at @OncLive. On Facebook, like us at OncLive, and follow our OncLive page on LinkedIn.
If you liked today’s episode of OncLive On Air, please consider subscribing to our podcast on Apple Podcasts, Spotify, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!
Thanks again for listening to OncLive On Air.
*OncLive On Air is available on: Apple Podcasts, Spotify, CastBox, Podcast Addict, Podchaser, RadioPublic, and TuneIn.
Advertisement
Related to this article
Oral azacitidine and cedazuridine met the end point of total cycle azacitidine exposure vs subcutaneous azacitidine in MDS or CMML.
Andrew Kuykendall, MD, discusses the FDA approval of rusfertide and how to apply it in clinical practice for polycythemia vera management.
The top 5 OncLive TV videos of the week cover insights in breast cancer, PV, myeloma, and CLL.
The FDA approved lirafugratinib in FGFR2+ cholangiocarcinoma and belzutifan plus lenvatinib in advanced ccRCC, and more.
Updated NCCN guidelines now recommend rusfertide as a Category 1 option for both low- and high-risk polycythemia vera.
An observational analysis showed a long-term OS benefit with Orca-T in adult patients undergoing allogeneic transplantation for hematologic malignancies.
FDA has granted fast track designation to LYT-200 plus a hypomethylating agent in relapsed/refractory high-risk myelodysplastic syndromes.
Advertisement
Advertisement
Trending on OncLive
1
Revisit Every OncLive On Air Episode From September 2026
2
Oral Azacitidine and Cedazuridine Meets Primary Pharmacokinetic End Point in MDS and CMML
3
Optune Pax Is Approved in Japan for Unresectable Locally Advanced Pancreatic Cancer
4
UTRxMYCN M1-14 Nets FDA Dual Designations in Soft Tissue Sarcoma
5